Catalent, Inc. (CTLT) EPS Estimated At $0.59

August 13, 2018 - By Frank Plummer

Catalent, Inc. (NYSE:CTLT) LogoInvestors sentiment decreased to 1.16 in Q1 2018. Its down 0.28, from 1.44 in 2017Q4. It dropped, as 23 investors sold Catalent, Inc. shares while 85 reduced holdings. 37 funds opened positions while 88 raised stakes. 127.42 million shares or 2.50% less from 130.69 million shares in 2017Q4 were reported.
Fincl Bank Of Ny Mellon stated it has 0.02% of its portfolio in Catalent, Inc. (NYSE:CTLT). Moreover, Commonwealth Of Pennsylvania Pub School Empls Retrmt Sys has 0.02% invested in Catalent, Inc. (NYSE:CTLT) for 35,946 shares. Mason Street Advsrs Limited Liability invested in 66,961 shares. Bernzott Cap reported 808,565 shares. Catalyst Advisors Lc reported 108 shares or 0% of all its holdings. 84,892 are owned by Cwm Ltd Company. Millennium Mgmt Ltd Liability Corporation accumulated 27,629 shares or 0% of the stock. 3.40M are owned by Franklin Resources Incorporated. Lombard Odier Asset Management (Usa) holds 85,000 shares or 0.25% of its portfolio. Quantbot Technologies L P accumulated 5,589 shares. Iguana Healthcare Management Ltd Co accumulated 30,000 shares or 0.81% of the stock. Illinois-based Citadel Advsr has invested 0.04% in Catalent, Inc. (NYSE:CTLT). Foundry Ltd accumulated 42,387 shares. State Of Tennessee Treasury Department invested in 150,000 shares or 0.03% of the stock. Royal Commercial Bank Of Canada reported 0% stake.

Since March 8, 2018, it had 0 insider purchases, and 2 selling transactions for $473,717 activity. 2,252 shares were sold by Fasman Steven L, worth $94,089.

Analysts expect Catalent, Inc. (NYSE:CTLT) to report $0.59 EPS on August, 28 before the open.They anticipate $0.05 EPS change or 7.81 % from last quarter’s $0.64 EPS. CTLT’s profit would be $85.47 million giving it 17.00 P/E if the $0.59 EPS is correct. After having $0.38 EPS previously, Catalent, Inc.’s analysts see 55.26 % EPS growth. The stock decreased 0.25% or $0.1 during the last trading session, reaching $40.12. About 509,640 shares traded. Catalent, Inc. (NYSE:CTLT) has risen 9.81% since August 13, 2017 and is uptrending. It has underperformed by 2.76% the S&P500.

Catalent, Inc. (NYSE:CTLT) Ratings Coverage

Among 2 analysts covering Catalent (NYSE:CTLT), 2 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Catalent had 2 analyst reports since March 21, 2018 according to SRatingsIntel. The stock of Catalent, Inc. (NYSE:CTLT) earned “Outperform” rating by Raymond James on Wednesday, March 21. The firm has “Overweight” rating by KeyBanc Capital Markets given on Wednesday, March 28.

Catalent, Inc. provides delivery technologies and development solutions for drugs, biologics, and consumer and animal health products worldwide. The company has market cap of $5.81 billion. It operates through three divisions: Softgel Technologies, Drug Delivery Solutions, and Clinical Supply Services. It has a 82.89 P/E ratio. The Softgel Technologies segment offers formulation, development, and manufacturing services for softgels, which are used in a range of customer products, such as prescription drugs, over-the-counter medications, dietary supplements, and unit-dose cosmetics.

Another recent and important Catalent, Inc. (NYSE:CTLT) news was published by which published an article titled: “Catalent (CTLT) Sees Q4 Revenue of 683 to $686 Million” on July 23, 2018.

Catalent, Inc. (NYSE:CTLT) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.